Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Nov;100(11):1940-1951.
doi: 10.1002/ajh.27768. Epub 2025 Jul 22.

Sickle Cell Diastolic Cardiomyopathy and Mortality Risk: A Novel Echocardiographic Framework for Prognostic Stratification

Affiliations
Multicenter Study

Sickle Cell Diastolic Cardiomyopathy and Mortality Risk: A Novel Echocardiographic Framework for Prognostic Stratification

Théo Simon et al. Am J Hematol. 2025 Nov.

Abstract

Cardiovascular complications are the leading cause of mortality in sickle cell anemia (SCA) patients. While extensive data have identified diastolic dysfunction (DD) to increase morbidity and mortality, the unique hemodynamic conditions inherent to SCA challenge the current recommendations to assess diastolic function. Thus, there is an urgent need to refine the echocardiographic definition of DD to improve risk stratification and therapeutic strategies in SCA patients. We analyzed data from the French multicentric Etendard cohort and compared them with an age- and sex-matched control group from the Copenhagen City Heart Study (CCHS). We focused on left ventricular diastolic parameters, specifically lateral e' velocity (e' lat), E/e' ratio, and indexed left atrial volume (LAVi), assessing their association with clinical outcomes over a 12-year follow-up. Etendard SCA patients (n = 379) had an early impaired diastolic function compared to the CCHS controls (n = 672). This was particularly obvious in young SCA patients (n = 252, age ≤ 38 years) in whom e' lat was associated with prognosis (p = 0.01), with an optimal cut-off value below 11 cm/s. Indeed, young SCA patients with DD had a fourfold increased 12-year mortality rate as compared with SCA patients without DD (16 vs. 4%, p < 0.001). Additionally, e' lat correlated with 6-min walk test, NT pro-BNP levels, diastolic blood pressure, and lactate dehydrogenase levels. In young SCA patients, our data contribute to refine the diagnosis of diastolic dysfunction evaluation. We highlight the prognostic value below 11 cm/s of lateral e' velocity and its association with key contributors of cardiac impairment such as hemolysis and systemic vasculopathy. Trial Registration: ClinicalTrials.gov identifier: NCT00434902.

Keywords: diastolic dysfunction; echocardiography; pulmonary hypertension; sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

P.B. received grants from ADDMEDICA, Fabre Foundation, NOVARTIS, and Bluebird in the past 36 months—consulting fees for ADDMEDICA, NOVARTIS, ROCHE, GBT, Bluebird, EMMAUS, HEMANEXT, AGIOS, and honoraria for lectures from NOVARTIS, ADDMEDICA, JAZZPHARMA. P.B. is a member of the NOVARTIS steering committee and cofounder of INNOVHEM.

Figures

FIGURE 1
FIGURE 1
Comparison of left ventricular diastolic function parameters between Etendard cohort and a matched subgroup of the Copenhagen City Heart Study. Panels A and B show e′ lat and LAVi evolution through age in both cohorts—Blue line refer as the limit of normal value in non‐SCA populations. Panels C–F compare value or distribution of diastolic function parameters across both cohors. *** stands for p < 0.001. [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
(A) Kaplan–Meier curves with log rank analysis evaluating e′ lat ≤ 11 cm/s impact on 12‐year mortality. (B) 12‐year survival function plots with e′ lateral wave and 95% individual confidence interval. [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3
FIGURE 3
Kaplan–Meier curves with log rank analysis evaluating e′ lat ≤ 11 cm/s impact on short term mortality in Drepacoeur cohort. [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Hammoudi N., Lionnet F., Redheuil A., and Montalescot G., “Cardiovascular Manifestations of Sickle Cell Disease,” European Heart Journal 41, no. 13 (2020): 1365–1373. - PubMed
    1. Platt O. S., Brambilla D. J., Rosse W. F., et al., “Mortality in Sickle Cell Disease – Life Expectancy and Risk Factors for Early Death,” New England Journal of Medicine 330, no. 23 (1994): 1639–1644. - PubMed
    1. Anthi A., Machado R. F., Jison M. L., et al., “Hemodynamic and Functional Assessment of Patients With Sickle Cell Disease and Pulmonary Hypertension,” American Journal of Respiratory and Critical Care Medicine 175, no. 12 (2007): 1272–1279. - PMC - PubMed
    1. d'Humières T., Bouvarel A., Boyer L., et al., “Cardiac Diastolic Maladaptation Is Associated With the Severity of Exercise Intolerance in Sickle Cell Anemia Patients,” Scientific Reports 14, no. 1 (2024): 11095. - PMC - PubMed
    1. d'Humières T., Sadraoui Z., Savale L., et al., “Atrial Arrhythmia in Sickle Cell Anemia Adults: A Missing Link Towards Understanding and Preventing Strokes,” Blood Advances 8 (2024): 5625–5638. - PMC - PubMed

Publication types

MeSH terms

Associated data